5.900GBp-0.84%Mkt Cap: 63.04M GBpP/E: —Last update: 2026-06-01
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Fera…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap63.04M GBp
Enterprise Value61.58M GBp
Revenue (TTM)49.70M GBp
Gross Profit23.04M GBp
Net Income (TTM)-17.66M GBp
Revenue/Share0.0560 GBp
Last Price5.900 GBp
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)6.13
PEG—
EV/EBITDA-6.89
EV/Revenue1.24
P/S1.28
P/B-5.63
EPS (TTM)-0.01
EPS (Forward)0.01
52W Range
2.30035% of range12.50
52W High12.50 GBp
52W Low2.300 GBp
Profitability
Gross Margin46.36%
Oper. Margin-15.07%
EBITDA Margin-17.98%
Profit Margin-35.52%
ROE117.10%
ROA-27.07%
Growth
Revenue Growth40.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.38M GBp
CapEx (TTM)300.00K GBp
FCF Margin12.55%
FCF Yield9.90%
Net Debt18.51M GBp
Net Debt/EBITDA-2.07
Balance Sheet
Debt/Equity-2.00
Current Ratio0.90
Quick Ratio0.72
Book Value/Sh-0.0106 GBp
Cash/Share0.0160 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)17.33 GBp
Target Range14.00 GBp – 23.00 GBp
# Analysts3
Ownership
Shares Out.1.07B
Float278.83M
Insiders71.28%
Institutions3.20%
Technical
SMA 507.931 (-25.6%)
SMA 2008.695 (-32.1%)
Beta1.88
S&P 52W Chg27.94%
Avg Vol (30d)2.73M
Avg Vol (10d)2.56M
Technical Indicators
RSI (14)25.5
MACD-0.6270
MACD Signal-0.5945
MACD Hist.-0.0326
BB Upper8.079 GBp
BB Middle6.744 GBp
BB Lower5.408 GBp
BB Width39.61%
ATR (14)0.4767 GBp
Vol Ratio (20d)0.41x